

1 STEPHANIE M. HINDS (CABN 154284)  
United States Attorney

2 THOMAS S. COLTHURST (CABN 99493)  
3 Chief, Criminal Division

4 JEFFREY B. SCHENK (CABN 234355)  
JOHN C. BOSTIC (CABN 264367)  
5 ROBERT S. LEACH (CABN 196191)  
KELLY I. VOLKAR (CABN 301377)  
6 Assistant United States Attorneys

7 150 Almaden Boulevard, Suite 900  
San Jose, California 95113  
8 Telephone: (408) 535-5061  
9 Fax: (408) 535-5066  
Kelly.Volkar@usdoj.gov

10 Attorneys for United States of America

11 UNITED STATES DISTRICT COURT  
12 NORTHERN DISTRICT OF CALIFORNIA  
13 SAN JOSE DIVISION

|                              |   |                                     |
|------------------------------|---|-------------------------------------|
| 14 UNITED STATES OF AMERICA, | ) | Case No. 18-CR-00258 EJD            |
|                              | ) |                                     |
| 15 Plaintiff,                | ) | UNITED STATES' OPPOSITION TO        |
|                              | ) | DEFENDANT ELIZABETH HOLMES' MOTION  |
| 16 v.                        | ) | FOR NEW TRIAL PURSUANT TO FEDERAL   |
|                              | ) | RULE OF CRIMINAL PROCEDURE 33 BASED |
| 17 ELIZABETH HOLMES,         | ) | ON DOCUMENTS RELATED TO THE LIS     |
|                              | ) | DATABASE (ECF NO. 1577)             |
| 18 Defendant.                | ) |                                     |
|                              | ) | Date: October 3, 2022               |
|                              | ) | Time: 1:30 p.m.                     |
|                              | ) | Court: Hon. Edward J. Davila        |
|                              | ) |                                     |
|                              | ) |                                     |

TABLE OF CONTENTS

1

2 INTRODUCTION .....1

3 BACKGROUND.....2

4     A. Proceedings Before Defendant Holmes’ Trial.....2

5     B. Proceedings During Defendant Holmes’ Trial.....5

6     C. Proceedings Before Co-Defendant Balwani’s Trial.....6

7     D. Proceedings During Co-Defendant Balwani’s Trial.....7

8     E. Defendant’s Untimely Motion for a New Trial.....9

9 ARGUMENT.....9

10     A. Defendant’s Rule 33 Motion re: LIS-Related Documents Does Not Satisfy the Stringent

11         Requirements for a New Trial Based on Newly Discovered Evidence.....9

12         1. The LIS-Related Documents Do Not Provide New Information.....10

13         2. Defendant Was Not Diligent.....12

14         3. The LIS-Related Documents Are Not Material.....14

15         4. The LIS-Related Documents Are Cumulative and Impeachment Evidence.....16

16         5. The LIS-Related Documents Would Not Result in an Acquittal.....18

17     B. Defendant Is Not Entitled to a New Trial Because No Violation of *Brady v. Maryland*, 373 U.S.

18         83 (1963), Occurred.....21

19         1. The LIS-Related Documents Are Not Admissible or Exculpatory.....21

20         2. The Substance of the LIS-Related Documents Was Not Suppressed.....22

21         3. The LIS-Related Documents Are Not Material Because the Result of the Proceeding Would

22             Not Have Been Different.....23

23     C. An Evidentiary Hearing Is Unnecessary.....25

24 CONCLUSION.....25

25

26

27

28

TABLE OF AUTHORITIES

Cases

1

2

3

4 *Barker v. Fleming*,  
423 F.3d 1085 (9th Cir. 2005) ..... 23

5

6 *Brady v. Maryland*,  
373 U.S. 83 (1963)..... 2, 21

7 *Buchanan v. United States*,  
2013 WL 4761025 (S.D. Cal. Sept. 4, 2013)..... 23

8

9 *Carter v. Bell*,  
218 F.3d 581 (6th Cir. 2000) ..... 22

10

11 *Comstock v. Humphries*,  
786 F.3d 701 (9th Cir. 2015) ..... 22

12 *DeBerry v. Wolff*,  
513 F.2d 1336 (8th Cir. 1975) ..... 23

13

14 *Giglio v. United States*,  
405 U.S. 150 (1972)..... 2

15

16 *Jencks v. United States*,  
353 U.S. 657 (1957)..... 2, 3, 6, 7

17

18 *Kyles v. Whitley*,  
514 U.S. 419 (1995)..... 21, 23

19 *Morris v. Ylst*,  
447 F.3d 735 (9th Cir. 2006) ..... 22

20

21 *United States v. Agurs*,  
427 U.S. 97 (1976)..... 23

22

23 *United States v. Bagley*,  
473 U.S. 667 (1985)..... 21

24 *United States v. Bakshinian*,  
65 F. Supp. 2d 1104 (C.D. Cal. 1999) ..... 17

25

26 *United States v. Brugnara*,  
856 F.3d 1198 (9th Cir. 2017) ..... 13

27

28 *United States v. Caballero*,  
745 F. App'x 32 (9th Cir. 2018) ..... 10

1 *United States v. Cohen*,  
 2 685 F. App’x 609 (9th Cir. 2017) ..... 17

3 *United States v. George*,  
 4 420 F.3d 991 (9th Cir. 2005) ..... 14, 16

5 *United States v. Hanoum*,  
 6 33 F.3d 1128 (9th Cir. 1994) ..... 14

7 *United States v. Harrington*,  
 8 410 F.3d 598 (9th Cir. 2005) ..... 9, 17

9 *United States v. Henderson*,  
 10 250 F. App’x 34 (5th Cir. 2007) ..... 23

11 *United States v. Hinkson*,  
 12 585 F.3d 1247 (9th Cir. 2009) (*en banc*) ..... 10, 17, 18

13 *United States v. Kenny*,  
 14 645 F.2d 1323 (9th Cir. 1981) ..... 20

15 *United States v. Kohring*,  
 16 637 F.3d 895 (9th Cir. 2011) ..... 21

17 *United States v. Lockett*,  
 18 919 F.2d 585 (9th Cir. 1990) ..... 12

19 *United States v. Moalin*,  
 20 973 F.3d 977 (9th Cir. 2020) ..... 23

21 *United States v. Nace*,  
 22 561 F.2d 763 (9th Cir. 1977) ..... 25

23 *United States v. Prantil*,  
 24 764 F.2d 548 (9th Cir. 1985) ..... 18

25 *United States v. Reyes-Alvarado*,  
 26 963 F.2d 1184 (9th Cir. 1992) ..... 25

27 *United States v. Reyes-Garcia*,  
 28 No. 10-CR-348-KJM, 2011 WL 6260357, at \*3 (E.D. Cal. Dec. 15, 2011) ..... 24

*United States v. Runyan*,  
 290 F.3d 223 (5th Cir. 2002) ..... 22

*United States v. Sarno*,  
 73 F.3d 1470 (9th Cir. 1995) ..... 24

1 *United States v. Showalter*,  
 2 569 F.3d 1150 (9th Cir. 2009) ..... 12

3 *United States v. Skilling*,  
 4 554 F.3d 529 (5th Cir. 2009) *aff'd in part and vacated in part on other grounds*,  
 561 U.S. 358 (2010)..... 23

5 *United States v. Slatten*,  
 6 865 F.3d 767 (D.C. Cir. 2017) ..... 25

7 *United States v. Steel*,  
 8 759 F.2d 706 (9th Cir. 1985) ..... 9

9 *United States v. Tamez*,  
 44 F. App'x 790 (9th Cir. 2002) ..... 12, 13

10 *United States v. Waggoner*,  
 11 339 F.3d 915 (9th Cir. 2003) ..... 18, 21

12 *United States v. Weber*,  
 13 721 F.2d 266 (9th Cir. 1983) ..... 17

14 *United States v. Wooten*,  
 377 F.3d 1134 (10th Cir. 2004) ..... 23

15 Rules

16 Fed. R. Evid. 401 ..... 17

17 Fed. R. Evid. 403 ..... 17, 18

18

19

20

21

22

23

24

25

26

27

28

## INTRODUCTION

1  
2 The government incorporates by reference the introduction, procedural background, and legal  
3 standard sections of its contemporaneously filed Opposition to Defendant Elizabeth Holmes' Rule 33  
4 Motion re: Government Argument in Balwani Trial, filed at ECF No. 1585, and provides below  
5 additional factual background specific to prior litigation regarding Theranos' Laboratory Information  
6 System ("LIS"). The Court should deny Defendant's untimely Rule 33 Motion re: LIS-Related  
7 Documents (ECF No. 1577) because it does not identify new information—where Defendant admits to  
8 having known the substantive information since October 2020—that is material or likely to alter her  
9 conviction on investor-related counts. Defendant claims this information is material to her false  
10 statements about the accuracy and reliability of Theranos' blood tests, which is only one subcategory  
11 amongst the false statements she told investors regarding the capabilities of Theranos' device (itself also  
12 only one category of false misrepresentations among many). *See* ECF No. 1577 at 13, 16, 20.  
13 Critically, however, when the Court partially granted co-Defendant Ramesh "Sunny" Balwani's motion  
14 to compel, the Court left undisturbed its prior rulings and barred Balwani from presenting testimony  
15 regarding "whether the LIS database and its contents would have demonstrated Theranos tests were  
16 accurate and reliable" and similarly prohibited the government from responding in any rebuttal case on  
17 this topic. ECF No. 1464 at 9, 12. Thus, even if Defendant's claim that old information produced in a  
18 new format was relevant to a subpart within a subpart of the categories of false misrepresentations she  
19 made to investors, she cannot show that it would have led to a different outcome under any standard.

20 Furthermore, Defendant claims the documents at issue would have been relevant to preparing her  
21 defense strategy, but the facts show that she had all the relevant information and simply made the  
22 strategic choice not to pursue a defense at trial arguing about who was at fault for the loss of the LIS  
23 database. Indeed, prior to her trial, the Court deferred ruling on her motion to compel production of  
24 these documents and yet Defendant never pursued them further. By contrast, co-Defendant Balwani  
25 went forward with the defense Defendant claims was not available to her—even though both parties had  
26 the same information before their respective trials—and was subsequently convicted on all twelve  
27 counts in the Third Superseding Indictment ("TSI"). *See* ECF No. 1507; ECF No. 469 (TSI).  
28 Therefore, this Court should deny her request for a new trial and for an evidentiary hearing.

## BACKGROUND

The Court has heard the facts surrounding the nature and destruction of Theranos' LIS on numerous occasions, and the government incorporates by reference its prior filings and arguments.<sup>1</sup> *See also* ECF No. 887 at 1–7 (detailing facts surrounding the government's attempt to obtain the LIS and Theranos' subsequent destruction of it). The government highlights below the facts relevant to resolving the present motion before the Court.

### A. Proceedings Before Defendant Holmes' Trial

On October 29, 2020, in response to Defendants' requests, the government disclosed more than twenty pages of information that Defendants may view as potentially discoverable under *Brady v. Maryland*, 373 U.S. 83 (1963), *Giglio v. United States*, 405 U.S. 150, 154 (1972), or *Jencks v. United States*, 353 U.S. 657 (1957) ("October 2020 Letter"). *See* ECF No. 732-2; 5/4/21 Tr. at 55:17–25 (Defendant Holmes' counsel describing letter as "the longest *Brady* letter I've ever received" that provides the LIS-related chronology "in excruciating detail"). Subsequently, Defendant served the government with her First Amended Witness List, including for the first time members of the prosecution team by name and other government employees by their titles as listed in the October 2020 Letter. *See, e.g.*, ECF No. 1003.

Defendant moved *in limine* to exclude (as relevant here) both (a) any reference by the government regarding Defendant's role or other Theranos' executives' roles in destroying the LIS in August 2018 (*see* ECF No. 565 at 4) and (b) so-called "anecdotal" testimony by patient-victims and their physicians (*see* ECF No. 563). During the three-day hearing on Defendant's voluminous motions *in limine*, a substantial portion of the first day was spent discussing this topic. *See, e.g.*, 5/4/21 Tr. at 40–100. Throughout that portion of the hearing, Defendant repeatedly asserted that the absence of the

---

<sup>1</sup> The government incorporates by reference its prior briefing, including all supporting declarations and exhibits, and oral argument on this subject. *See, e.g.*, ECF No. 682, 846, 1181, 1426, 1440, 1454; *United States v. Holmes*, 05/04/2021 Hearing Transcript ("5/4/21 Tr.") at 45–68, 79–85; *United States v. Holmes*, 07/07/2021 Hearing Transcript ("7/7 Tr."); *United States v. Holmes*, 11/10/2021 Trial Transcript ("11/10 Tr.") at 5877–5889; *United States v. Holmes*, 11/19/2021 Trial Transcript ("11/19 Tr.") at 7100–7104; *United States v. Balwani*, 02/08/2022 Hearing Transcript ("2/8 Tr."); *United States v. Balwani*, 05/11/2022 Trial Transcript ("5/11 Tr.") at 5291–5329; *United States v. Balwani*, 05/23/2022 Trial Transcript ("5/23 Tr.").

1 LIS database was reason to preclude patient-victims from testifying about the inaccuracy and  
2 unreliability of Theranos tests because Defendant would be unable to show the “statistical  
3 insignificance” of their testimony without the LIS. *Id.* For example, Defendant asserted that the patient  
4 testimony was “not relevant [ ] because they have not established that causal link either specifically in  
5 the LIS database or statistically,” and that “the prejudicial impact on such anecdotal evidence just  
6 swamps any probative value based on the statistically [sic] analysis and particularly given the lack of  
7 access to the LIS to refute those allegations.” *Id.* at 62–65; *see also id.* at 58, 90–92, 96–98. The  
8 government responded that this is not a products liability case and thus the absence of the LIS database  
9 should not preclude individual patient-victims from testifying, particularly when there are several other  
10 categories of evidence that will support their testimony demonstrating that Theranos was not capable of  
11 consistently producing accurate and reliable test results to patients. *See, e.g., id.* at 67, 70–72, 81–84;  
12 *see also* ECF No. 469 (TSI) ¶ 16.

13 While Defendant vehemently argued that she should be permitted to argue the government’s  
14 failure to meet its burden of proof with respect to the patient-related counts because of its lack of  
15 statistical analysis of accuracy and reliability problems at Theranos, Defendant just as vigorously argued  
16 that what happened to the LIS database and who was responsible for its destruction was “irrelevant to  
17 this case[.]” *See, e.g.,* 5/4/21 Tr. at 49–50, 54–58, 93–98. Defendant asserted that she could call  
18 members of the prosecution team and government support staff members as fact witnesses to get to the  
19 bottom of that question, but Defendant did not intend to go into that “side trial” or “mini-trial.” *See id.*  
20 at 54–56 (“[the government’s] own internal litigation support expert who would be a witness in this mini  
21 trial says you can go and get all of that hardware and recreate it within the U.S. Attorney’s Office, but  
22 they never did that”), 93 (“members of the government team [ ] who are witnesses in this case because  
23 of their involvement in the facts”), 94–95 (“So all of that, again, should be out. We’re not looking to put  
24 prosecutors on the witness stand.”), 98 (“Our goal is [ ] to avoid the side distraction[;] [i]t’s not core to  
25 this case.”).

26 The Court denied Defendant’s motion *in limine* to exclude the “anecdotal” testimony from  
27 patient-victims—but permitted Holmes to argue the lack of statistical significance of that evidence.  
28 ECF No. 798 at 47–50, 56–58. The Court deferred until trial deciding whether a fact issue arising over



1 “fault in destruction of the database” would be necessary, depending on the “arguments Holmes raises at  
2 trial” as well as “whether [ ] any sort of jury instruction on the issue” would be necessary. *Id.* at 58.  
3 Approximately ten days later, Defendant moved to suppress several categories of evidence regarding the  
4 patient-related counts based on the absence of the LIS database. ECF No. 810; *see also* ECF No. 846  
5 (government’s opposition). In that same motion, Defendant requested an evidentiary hearing to resolve  
6 the alleged “factual dispute” regarding responsibility for the loss of the LIS database and “questions  
7 about the government’s conduct in this case that need to be explored”; Defendant also requested further  
8 production of the documents underlying the government’s October 2020 Letter. ECF No. 810 at 11–12.  
9 During the hearing on Defendant’s motion to suppress, her counsel reiterated both that she knew the  
10 facts underlying the government’s October 2020 Letter—including the identity of who was involved—  
11 and that the absence of the LIS database related to the patient (not investor) counts. 7/7 Tr. at 11 (“the  
12 prosecutors prosecuting this case repeatedly disregarded advice from their own support staff regarding  
13 steps that they should take to access and preserve the LIS database”), 30 (“[the government] knew that  
14 some doctors who had sent patients to LIS believed that their test results were accurate and reliable[;]  
15 [t]hose test results of course resided in the LIS”), 34–36 (“[W]ith respect **to the patient counts** that  
16 [information in LIS] would be exculpatory evidence, your honor, because their claim is that Theranos  
17 technology was incapable of producing accurate and reliable results.” (emphasis added)).

18 On August 4, 2021, the Court denied Defendant Holmes’ motion to suppress, including her  
19 request for an evidentiary hearing and for further production of documents. ECF No. 887 at 17–18.  
20 Specifically, the Court found the exculpatory nature of the documents underlying the government’s  
21 October 2020 Letter to be “speculative,” the evidence post-August 31, 2018 to be “irrelevant,” and that  
22 the government did not act in bad faith. ECF No. 887. The Court found that “[t]he LIS database  
23 information alone would not provide a conclusive determination of whether the Theranos blood tests  
24 were accurate, and *it could just as likely contain incriminating evidence to the contrary.* Any  
25 exculpatory value is therefore speculative in nature.” ECF No. 887 at 10 (emphasis added); *see id.* at 8–  
26 11. The Court also noted that, while Defendant Holmes asserted the LIS database would include  
27 exculpatory information, she never “informed the Government of the database’s purported exculpatory  
28 value either prior to filing the present motion [to suppress] or prior to the decommissioning of the

1 original LIS database,” nor did she seek to aid the government in its efforts to obtain a copy. ECF No.  
2 887 at 9. Moreover, the Court held that any evidence of the government’s conduct after Theranos  
3 destroyed the LIS database in late August 2018 is irrelevant. ECF No. 887 at 14. The Court rejected  
4 Defendant’s argument that the government could have reconstructed the database because the Court  
5 found that the evidence “either contradicts her proposition or is of low persuasive value.” ECF No. 887  
6 at 13–14; *see also id.* at 5, 16. Based in part on the above findings, the Court denied Defendant Holmes’  
7 request for further production of documents underlying the government’s October 2020 Letter because  
8 “Holmes has not indicated why any of the information or evidence she seeks is relevant, helpful in  
9 establishing her defense, not cumulative, or not exempt from disclosure due to deliberative privilege  
10 and/or work product protection.” ECF No. 887 at 17; *see id.* at 17–18. The Court specifically held: “To  
11 the extent [defendant] seeks the **identities of government employees** and documents cited for the  
12 purpose of delving into the Government’s actions with respect to the LIS database after August 31,  
13 2018, that information is not relevant[.]” *Id.* at 17 (emphasis added).

14 The Court also specifically acknowledged that circumstances could change if the government  
15 were to call witnesses to discuss the attempted collection of the LIS database, and “defer[red] ruling on  
16 whether the Government must provide additional related documents” described in the October 2020  
17 Letter if that were to occur. *Id.* at 18; *see also* ECF No. 1577 at 7 (acknowledging this holding).

#### 18 **B. Proceedings During Defendant Holmes’ Trial**

19 The LIS database continued to be a topic of frequent discussion during Defendant’s trial. *See,*  
20 *e.g., United States v. Holmes*, 09/29/2021 Trial Transcript (“9/29 Tr.”) at 2371–2374; 11/10 Tr. at 5877–  
21 5889; 11/19 Tr. at 7100–7104. Defendant’s counsel repeatedly represented to the Court and to the  
22 government that she was not “put[ting] at issue at trial the government’s conduct” and thus, while  
23 intending to present her defense of the failure to provide a statistical analysis, there was no basis for the  
24 government to call additional fact witnesses at trial to address who was at fault for the missing LIS  
25 database. *See* 11/10 Tr. at 5877–5889; 11/19 Tr. at 7100–7104 (preserving motion to suppress issues for  
26 record and noting that the “record is exactly where it was at the time that we first made this motion”  
27 since Defendant did not introduce evidence at trial regarding the government’s conduct); *see also*  
28 Exhibit 1 (“At trial, Ms. Holmes has not blamed the government for failing to gather and preserve the

1 LIS database [and therefore] the government cannot introduce evidence concerning the loss of the LIS  
2 database.”). In closing argument, as forecast, Defendant did not address the LIS database, but did  
3 emphasize several related points such as the “anecdotal” nature of the patient-victims the government  
4 called to testify and the lack of “statistical” evidence presented by the government. *See United States v.*  
5 *Holmes*, 12/17/2021 Trial Transcript (“12/17 Tr.”) at 9216–9227. The jury ultimately acquitted  
6 Defendant on the patient-related counts. ECF No. 1235.

### 7 C. Proceedings Before Co-Defendant Balwani’s Trial

8 Before the start of his trial, co-Defendant Balwani was in the same position as Defendant Holmes  
9 with respect to admissibility of information relating to the LIS database. Specifically, on November 19,  
10 2021, co-Defendant Balwani adopted Defendant Holmes’ motion *in limine* (re: LIS) and motion to  
11 suppress and again moved for production of “all documents related to [the government’s] decision not to  
12 capture the LIS data.” ECF No. 1156 at 73–74. The parties held a hearing solely on this topic. *See*  
13 *generally* 2/8 Tr. One difference is that Balwani disclosed a potential expert witness to discuss the LIS  
14 database (*see* ECF No. 1158), whereas Defendant never made such a disclosure.

15 On February 28, 2022, the Court denied co-Defendant Balwani’s adopted motions for the same  
16 reasons, as well as his demand for further production of documents underlying the October 2020 Letter.  
17 ECF No. 1326 at 30–37; *see id.* at 37 (“The Court finds that Balwani has provided no additional  
18 evidence or arguments that would warrant departing from its earlier ruling denying the motion to  
19 suppress, the request for an evidentiary hearing, and further production.”). The Court again held: “it is  
20 equally likely that [the LIS database] also contain[s] millions of *inculpatory* results” (*id.* at 31–32); “no  
21 bad faith on the part of the Government” including the fact that the prosecutors did not follow the  
22 suggestion of their Automated Litigation Specialist supervisor in part because the suggestion “was only  
23 one proposal among several” (*id.*); and that Balwani’s proposed expert on Microsoft SQL databases who  
24 proffered an opinion that the LIS database could be reconstructed was “unconvincing” given his lack of  
25 personal knowledge of Theranos’ LIS database (*id.* at 34). The Court again denied co-Defendant  
26 Balwani’s request for documents underlying the government’s October 2020 Letter. *Id.* at 37.

27 In sum, the Defendants were in the same position with respect to information in the October  
28 2020 Letter regarding the LIS database heading into their respective trials.

**D. Proceedings During Co-Defendant Balwani's Trial**

1           **D. Proceedings During Co-Defendant Balwani's Trial**  
2           Contrary to the strategy that Defendant Holmes took, co-Defendant Balwani decided to raise the  
3 issue of fault for the missing LIS database and argued that “the government never obtained the LIS” in  
4 his opening statement, specifically referencing facts disclosed in the October 2020 Letter. *United States*  
5 *v. Balwani*, 03/22/2022 Trial Transcript (“3/22 Tr.”) at 1105–1114; *see id.* at 1108 (“another technology  
6 specialist at the government told the investigators and prosecutors in this case . . . [to] go get the servers  
7 from Theranos that housed the hard drives . . . [but] the government never obtained the LIS[.]”). Thus,  
8 contrary to Defendant’s trial strategy, co-Defendant chose to place the fault for the loss of the LIS  
9 squarely at issue in his trial. *See id.* at 1113 (“I know that we have opened the door to something . . . .  
10 [T]he government can defend itself and argue that it wasn’t their fault.”); *see also* 5/11 Tr. at 5304–5305  
11 (responding to Court’s question if purpose was to “blame the government[,]” Balwani’s counsel said  
12 “Right[;] [i]f they had conducted a proper investigation . . . then we would have had [this] evidence”).

13           During co-Defendant Balwani’s trial, he again moved to compel the government to produce  
14 documents underlying certain paragraphs of the government’s October 2020 Letter. ECF Nos. 1425,  
15 1426 (government’s opposition). Rather than seeking all documents underlying the entirety of the  
16 October 2020 Letter, as both Defendants had sought in the past, this renewed motion sought a narrower  
17 subset of documents related to the government’s actions upon receiving an inaccessible copy of the LIS  
18 database from Theranos in the fall of 2018. *See* ECF Nos. 1425, 1425-3 at 3–9. Through argument  
19 before the Court, it became apparent that co-Defendant Balwani was intending to call his disclosed  
20 expert on Microsoft SQL databases to discuss the LIS database and was seeking the emails underlying  
21 certain parts of the October 2020 Letter to provide to that expert. *See* 5/11 Tr. at 5291–5329; *see*  
22 *generally* 5/23 Tr. The government moved to exclude co-Defendant Balwani’s LIS-related expert as  
23 irrelevant, among other grounds. ECF Nos. 1440, 1454.

24           The Court granted in part and denied in part Balwani’s renewed motion to compel and the  
25 government’s motion to exclude. ECF No. 1464. Specifically, the Court noted that co-Defendant  
26 Balwani, for the first time, “articulated a specific defense” whereas “previously, neither Balwani nor  
27 Holmes provided concrete positions on their plans for any LIS-related evidence sought.” *Id.* at 3. This  
28 newly articulated theory was co-Defendant Balwani’s “‘investigatory failure’ defense.” *Id.* The Court

1 reaffirmed its holding in prior orders that “the exculpatory value of the LIS database was speculative”  
2 but found that “the evidence now at issue before the Court **is not the LIS database itself**, but rather  
3 documents relating to the Government’s efforts to obtain the LIS and the data it contained.” *Id.* at 4–5  
4 (emphasis added). The Court returned to this distinction several times throughout its ruling, holding that  
5 Balwani’s expert “may not testify as to whether the LIS database and its contents would have  
6 demonstrated Theranos tests were accurate and reliable” and similarly precluding the government, in  
7 turn, from introducing such evidence in rebuttal. *Id.* at 9, 12. The Court noted that, while “the jury may  
8 very well ultimately find Balwani’s [‘investigatory failure’] defense unconvincing, *Brady* requires the  
9 Government to provide him [the documents] to present that defense[.]” and ordered the government to  
10 produce the narrow subset of documents identified. *Id.* at 6–7. The Court deferred ruling on  
11 admissibility of the documents, prohibited co-Defendant Balwani from “calling any members of the  
12 prosecution team as witnesses[.]” and prohibited his expert from opining on what “the Government  
13 *should* have done [as] outside the scope of his noticed testimony and expertise.” *Id.* at 7–8 & n.3, 11.

14 On June 2, 2022, per the Court’s order, the government produced to both Defendants eleven  
15 emails underlying specific paragraphs of the October 2020 Letter that co-Defendant Balwani asserted  
16 were necessary to present his “investigatory failure” defense (hereinafter “LIS-Related Documents”).  
17 *See* ECF No. 1577-2 at 2. Subsequently, co-Defendant Balwani’s expert on Microsoft SQL databases,  
18 Richard Sonnier, III, testified. *United States v. Balwani*, 06/09/2022 Trial Transcript (“6/9 Tr.”) at  
19 6711–6823. During Mr. Sonnier’s testimony, Balwani sought to admit only one of the emails  
20 underlying the October 2020 Letter and the Court admitted it for a limited purpose. *See id.* at 6741–  
21 6743 (admitting TX 20832 for a limited purpose); *see also id.* 6787–6789 (similarly admitting during the  
22 government’s cross-examination TX 5943, which has an additional response to the prior email thread);  
23 ECF Nos. 1577-3, 1577-5 (providing TX 20832 and TX 5943). On cross-examination, Mr. Sonnier  
24 admitted that the government had made “many requests” to Theranos and its subsequent assignee for the  
25 information in the LIS database (6/9 Tr. at 6751; *see also* ECF No. 846-9), that Mr. Sonnier had  
26 attempted to access the data stored on the same copy of the LIS database that Theranos provided to the  
27 government—who in turn produced the copy to both Defendants in this case—but he was unable to do  
28 so (6/9 Tr. at 6759–6760), and that he disagreed with several individuals in various roles at Theranos

1 who believed that it would be “very difficult to resuscitate” the LIS database once in storage (*see, e.g.*,  
2 *id.* at 6784–6786 (admitting TX 5897, the substance of which can be found at ECF No. 681-37), 6790–  
3 6798 (admitting TX 5917 for limited purpose); ECF No. 1577-4). The Court sustained co-Defendant  
4 Balwani’s objections to any questions relating to the substance (or lack thereof) within the LIS database  
5 based on the Court’s order. *See* 6/9 Tr. at 6798–6801. After Mr. Sonnier testified, the Court denied co-  
6 Defendant Balwani’s request for a missing evidence jury instruction permitting an adverse inference  
7 against the government due to the absence of the LIS database. *See* 6/9 Tr. at 6844–6888.

8 On July 7, 2022, a separate jury convicted co-Defendant Ramesh “Sunny” Balwani of all twelve  
9 counts in the TSI. ECF No. 1507.

#### 10 **E. Defendant’s Untimely Motion for a New Trial**

11 More than eight months after the jury’s verdict finding Defendant guilty on four investor-related  
12 counts, half a year after the agreed-upon extended deadline for such motions, three months after the LIS-  
13 Related Documents were produced, and mere weeks before her sentencing date, Defendant Holmes has  
14 filed three separate Rule 33 motions. ECF Nos. 1574, 1576, 1577. Defendant’s Rule 33 Motion re:  
15 LIS-Related Documents attaches six of the eleven emails regarding the government’s attempt to access  
16 the LIS database in 2018 that were produced pursuant to the Court’s order (ECF No. 1464) in early June  
17 2022 in connection with Balwani’s “investigatory failure” defense, but contain the same substantive  
18 information known to Defendant since October 2020. *See* ECF Nos. 1577, 1577-1.

### 19 **ARGUMENT**

#### 20 **A. Defendant’s Rule 33 Motion re: LIS-Related Documents Does Not Satisfy the** 21 **Stringent Requirements for a New Trial Based on Newly Discovered Evidence**

22 As previously described, to prevail on a motion for a new trial based on alleged newly  
23 discovered evidence, a defendant must demonstrate five separate and independent factors: (1) the  
24 evidence must be newly discovered; (2) the defendant was diligent in seeking the evidence; (3) the  
25 evidence is material to the issues at trial; (4) the evidence is not (a) cumulative or (b) merely  
26 impeaching; and (5) the evidence indicates the defendant would probably be acquitted in a new trial.  
27 *United States v. Harrington*, 410 F.3d 598, 601 (9th Cir. 2005) (citation omitted); *see also United States*  
28

1 *v. Steel*, 759 F.2d 706, 713 (9th Cir. 1985) (“This five-prong test is difficult to meet.”). Defendant fails  
2 to overcome her difficult burden on any of the five factors of the *Harrington* test for a new trial.

3 **1. The LIS-Related Documents Do Not Provide New Information**

4 As a threshold matter, the Court should deny Defendant’s Rule 33 Motion re: LIS-Related  
5 Documents because it does not refer to any “new” information. The Ninth Circuit has repeatedly upheld  
6 denials of Rule 33 motions based on newly discovered evidence where the substantive information—  
7 even if contained in a new or different form post-trial—was known before the jury reached a verdict.  
8 *See, e.g., United States v. Hinkson*, 585 F.3d 1247, 1264–65 (9th Cir. 2009) (*en banc*); *see also United*  
9 *States v. Caballero*, 745 F. App’x 32, 33 (9th Cir. 2018) (upholding finding that letter at issue did not  
10 constitute newly discovered evidence because “[e]ven if the letter itself was written after the trial,  
11 [defendant] was already aware of the substantive information contained therein from his counsel’s  
12 discussions with [the relevant witness] before trial”). In *Hinkson*, for example, the defendant sought a  
13 new trial on the basis of two affidavits from military personnel confirming that a key prosecution  
14 witness had testified falsely about his service record. 585 F.3d at 1257. The district court held that the  
15 evidence was not “new” because it contained no substantively new information, rather it merely  
16 reiterated the substance of evidence the defendant had attempted to admit during cross-examination at  
17 trial regarding this witness but now in a new format. *Id.* at 1257–58. The Ninth Circuit *en banc* upheld  
18 the district court’s conclusion, holding that the court did not abuse its discretion in finding that the two  
19 “affidavits, while newly written, did not provide any new *information* that was not already considered  
20 and rejected from evidentiary admission by the court[.]” *Id.* at 1264–65. So too here.

21 The LIS-Related Documents that the government produced to both Defendants in early  
22 June 2022 do not contain any “new” information. *Compare* ECF No. 732-2 at 19–24, *with* ECF Nos.  
23 1577-3–5, 1577-9–10, 1577-12. Rather, they are the documents underlying certain paragraphs of the  
24 October 2020 Letter, which Defendant has had for nearly a year before her trial and which, as her  
25 counsel asserted, describes the LIS-related chronology “in excruciating detail[.]” 5/4/21 Tr. at 55.  
26 Indeed, it is because of the information contained within the October 2020 Letter that Defendant sought  
27 to preclude the government from introducing aspects of post-2016 conduct during her trial, and her  
28 counsel described in May 2021—several months before her trial—the following:

1 Whatever happened thereafter with respect to that [LIS] database could be the subject of  
 2 a trial unto itself, certainly a mini trial within this trial that would involve witnesses.  
 3 There have [been] about 20 witnesses that have been interviewed or have given testimony  
 4 in connection with that matter. That does not include government personnel who would  
 5 be relevant to that case, **including every member of the prosecution team** who would  
 6 be a witness as to whether they took appropriate steps to obtain that evidence when they  
 7 knew about it for years and when it was produced to them.

8 ...  
 9 [T]hen [the government] went to its own internal experts within the U.S. Attorney's  
 10 Office and sought guidance as to how they might access that [copy]. They got very good  
 11 advice it turns out because it wasn't just the copy that was relevant that they had where  
 12 they had an issue with the key. That's a little bit of a red herring there. There was also a  
 13 copy on a server system that Theranos had. And their own expert, **their own internal  
 14 litigation support expert who would be a witness in this mini trial** says you can go  
 15 and get all of that hardware and recreate it within the U.S. Attorney's Office, but they  
 16 never did that.

17 ...  
 18 [T]hey could put this database back together within a month. So the copy is one thing.  
 19 The existing infrastructure is another. So the government's failure to move on that is a  
 20 significant issue with respect to this matter. Now, your honor, I have a solution to this  
 21 mess, which is Docket 565 at 4 [seeking to exclude this evidence]. This has nothing to  
 22 do with Elizabeth Holmes. Nothing. . . . [dismantling of LIS database] has no role in this  
 23 case which relates to Ms. Holmes. It's irrelevant under 401[.] . . . The fact that they tried  
 24 to get it later and make whoever shot who with respect to that is for another proceeding.  
 25 **That's not relevant to this case.**

26 5/4/21 Tr. at 55–58 (emphasis added); *cf.* ECF No. 1577.

27 Defendant seeks to circumvent the fact that she has known the underlying information for years  
 28 by focusing now on the *identity* of individuals shown in the emails but not specified in the October 2020  
 Letter. ECF No. 1577 at 8 & n.2, 13, 17, 19. This is a distinction without a difference. First and  
 foremost, Defendant knew and repeatedly asserted that the government attorneys referenced in the  
 October 2020 Letter were the same as members of the prosecution team because she repeatedly said as  
 much to the Court. *See* 5/4/21 Tr. at 55 (“including every member of the prosecution team who would  
 be a witness as to whether they took appropriate steps to obtain that evidence”), 56 (“[the government’s]  
 own internal litigation support expert who would be a witness in this mini trial”), 93 (“members of the  
 government team [ ] who are witnesses in this case because of their involvement in the facts”), 94–95  
 (“We’re not looking to put prosecutors on the witness stand.”); 7/7 Tr. at 11 (“the prosecutors  
 prosecuting this case repeatedly disregarded advice from their own support staff regarding steps that  
 they should take to access and preserve the LIS database”); 11/10 Tr. at 5881 (“and some of the



1 members of the team present may be witnesses with respect to that [i.e., the government’s responsibility  
2 and their failures re: LIS]”).

3           Second, after receiving the October 2020 Letter, Defendant added the names of the prosecuting  
4 attorneys to her witness list, as well as generic titles for government support staff members as identified  
5 in the letter, and those names and titles remained on Defendant’s witness list through the start of her  
6 trial. *See* ECF No. 1003 (listing John Bostic, Robert Leach, Jeffrey Schenk, “Government Attorneys  
7 LNU,” “Government Paralegal LNU,” “Automated Litigation Support Supervisor LNU,” and “USAO  
8 Employee in the Automated Litigation Support Unit LNU”). Beyond the person’s name rather than their  
9 title, Defendant only asserts in a footnote one purported factual difference between the October 2020  
10 Letter and the LIS-Related Documents that the government produced—whether co-Defendant Balwani  
11 *and* someone else knew how to decrypt the LIS database or co-Defendant Balwani could do so but it  
12 was unknown whether anyone else could. *See* ECF No. 1577 at 11 n.5. Defendant does not explain  
13 how this purported difference would alter any fact with respect to her trial and thus the Court should  
14 disregard this assertion as irrelevant and immaterial.

15           The Ninth Circuit has long held that “a court must exercise great caution in considering evidence  
16 to be ‘newly discovered’ when it existed all along and was unavailable” solely because defendant did  
17 not call the relevant witness to testify to the facts at trial. *United States v. Lockett*, 919 F.2d 585, 591–92  
18 (9th Cir. 1990); *see also United States v. Showalter*, 569 F.3d 1150, 1154–55, 1157 (9th Cir. 2009)  
19 (affirming district court’s denial of defendant’s request to withdraw guilty plea because witness  
20 declarations were not “new” evidence as the defendant could have compelled the witnesses to testify on  
21 his behalf at trial); *United States v. Tamez*, 44 F. App’x 790, 791 (9th Cir. 2002). Similarly, here, the  
22 Court should deny Defendant’s Rule 33 Motion re: LIS-Related Documents because it does not refer to  
23 any “new” information.

## 24           **2. Defendant Was Not Diligent**

25           The Court should deny Defendant’s Rule 33 Motion re: LIS-Related Documents because she was  
26 not diligent in seeking the documents in addition to the known information underlying the October 2020  
27 Letter during her trial. Specifically, heading into her trial, Defendant had the same information and was  
28 in the same procedural posture as her co-Defendant Balwani was before his trial. She could have chosen

1 to “argue[ ] that the LIS database is unavailable because of the Government’s failure to obtain it” and  
2 that would have opened the door to the government—which was otherwise precluded from—introducing  
3 evidence about “Theranos’ nefarious destruction of the LIS database[,]” which, in turn, would have  
4 permitted Defendant Holmes to renew her request for documents underlying the October 2020 Letter per  
5 the Court’s deferred ruling. ECF Nos. 798 at 57–58, 887 at 18 (deferring ruling in case government  
6 called witnesses related to the destruction of LIS database and subsequent attempts to obtain a  
7 functioning copy); *see also* ECF No. 1577 at 7 (acknowledging this holding). Defendant knew who the  
8 relevant witnesses were as shown by her witness list (ECF No. 1003), she had a letter from the  
9 government to her counsel regarding the LIS database listed as a potential exhibit in her case-in-chief on  
10 her exhibit list at the start of her trial (ECF No. 1002 at 30), and she accounted for a potential “missing  
11 evidence” instruction in her pretrial proposed jury instructions (ECF No. 809 at 91).

12 The choice was entirely Defendant’s to make but she strategically elected not to argue that the  
13 government failed to obtain the LIS database. *See* Exhibit 1. Toward the end of her trial, the  
14 government sought clarification regarding whether Defendant was going to argue that the LIS was  
15 missing because of the government’s actions in order to determine the remaining witnesses it needed to  
16 call during its case-in-chief, and Defendant responded that she would not make that argument. *See id.*;  
17 11/10 Tr. at 5877–5889; 11/19 Tr. at 7100–7104 (confirming for the Court at the close of the  
18 government’s case-in-chief that Defendant had not “put at issue at trial the government’s conduct” and  
19 did “not put any evidence forward” on that topic). While Defendant initially sought a “missing  
20 evidence” jury instruction (ECF 809 at 91), by the end of trial she dropped that request (ECF No. 1188).  
21 By contrast, Balwani made a different choice and that resulted in a different outcome—including  
22 unsuccessfully requesting a “missing evidence” instruction. This Court should reject Defendant’s  
23 request for a new trial on the basis of a trial defense that she had equal access to make but she chose to  
24 forego. *See, e.g., United States v. Brugnara*, 856 F.3d 1198, 1206–07 (9th Cir. 2017) (affirming district  
25 court’s denial of motion for new trial by finding defendant did not act diligently and noting “[i]t is not  
26 uncommon that a party fails to act diligently when he does not take advantage of reasonably available  
27 means to obtain known or suspected evidence before or at least during trial”).

### 3. The LIS-Related Documents Are Not Material

1  
2 Defendant's motion also fails to meet the materiality requirement because her arguments expose  
3 a fundamental mismatch between the evidence she claims is newly discovered and the result she seeks.  
4 Evidence is material only when it "relates to the elements of the crime charged" and would impact  
5 "whether [the defendant] is innocent or guilty of the [convicted] crimes[.]" *United States v. Hanoum*, 33  
6 F.3d 1128, 1130–31 (9th Cir. 1994) (holding new evidence showing ineffective assistance of counsel is  
7 not material because the evidence itself was not new and how counsel failed to use such evidence did  
8 not relate to innocence or guilt of defendant); *see also United States v. George*, 420 F.3d 991, 1001 (9th  
9 Cir. 2005) (holding newly discovered evidence was not material where it established "a collateral point"  
10 otherwise developed at trial). Here, Defendant makes a feeble attempt to make a tenuous connection  
11 between the LIS-Related Documents and the investor-related counts on which she was convicted. ECF  
12 No. 1577 at 16. The Court must accept multiple false premises to reach her conclusion: first, that the  
13 LIS-Related Documents have any relevance to the accuracy and reliability of Theranos testing when the  
14 Court's order finds otherwise; second, that the LIS database if it were accessible would definitively  
15 prove that Theranos consistently provided accurate and reliable blood tests contrary to the Court's  
16 finding and the testimony of former Theranos employees who worked with the database in real-time;  
17 and third, that the speculative exculpatory evidence within LIS would undermine one subpart of a  
18 subpart of misrepresentations Defendant made to investor-victims in a manner that would somehow alter  
19 the jury's verdict on those counts. The Court should reject this house-of-cards approach and find the  
20 LIS-Related Documents immaterial to the counts on which Defendant Holmes was convicted.

21 The LIS-Related Documents are not relevant to demonstrating whether Theranos could provide  
22 accurate and reliable blood tests. *See, e.g.*, ECF Nos. 732-2 at 19–24 (describing substance of emails),  
23 1577-3, 1577-4, 1577-5, 1577-9, 1577-10, 1577-12 (attaching six of the eleven produced emails). As  
24 described in the prior section, Defendant was in the exact same position pretrial as Balwani in  
25 determining whether to pursue an "investigatory failure" defense—indeed, she had the relevant  
26 witnesses listed on her potential trial witness list—but Defendant opted not to pursue that defense. *Cf.*  
27 ECF No. 1577 at 13, 19 (material to preparing defense strategy). Implicitly acknowledging this gap,  
28 Defendant switches back to the theory she has consistently articulated—and the Court has consistently

1 rejected—since before her trial began: that the absence of the LIS database somehow prevents the  
2 government from proving that Theranos was unable to provide accurate and reliable blood tests. *See*  
3 ECF No. 1577 at 11, 13–16. But the Court did not order the government to produce the LIS-Related  
4 Documents for this purpose, nor admit them at co-Defendant’s trial for this purpose. ECF No. 1464 at  
5 4–7; *see* 6/9 Tr. at 6741–6743, 6784–6798. Rather, the Court explicitly prohibited either the  
6 government or co-Defendant Balwani from eliciting further testimony regarding the inaccuracy and  
7 unreliability of Theranos testing and even sustained objections by Balwani when the government sought  
8 to elicit testimony regarding the gaps in data in the LIS database. ECF No. 1464 at 9, 12; *see* 6/9 Tr. at  
9 6798–6801. The Court reaffirmed that “the exculpatory value of the LIS database was speculative” but  
10 found that “the evidence now at issue before the Court **is not the LIS database itself**, but rather  
11 documents relating to the Government’s efforts to obtain the LIS and the data it contained.” ECF No.  
12 1464 at 4–5 (emphasis added). Put differently, Defendant cannot point to what was gained in these  
13 underlying eleven documents with respect to attempting to prove her theory that Theranos could provide  
14 accurate and reliable tests—especially given everyone agrees that the LIS database is still inaccessible to  
15 all parties. *See, e.g.*, 6/9 Tr. at 6759–6760 (co-Defendant’s expert attempted and failed to access data  
16 within copy of LIS database provided to government and Defendants).

17 Furthermore, as the government has argued more extensively elsewhere, the LIS database would  
18 have been a “powerful tool” to identify additional patient-victims and quality-control data, but it would  
19 not have allowed the parties to sort accurate from inaccurate patient results or determine an overall  
20 failure rate for Theranos’ blood tests. *See, e.g.*, ECF Nos. 846 at 7–8, 1440 at 5–7; 5/4/21 Tr. at 67, 70–  
21 72, 81–84; *cf.* ECF No. 1577 at 13–15. Indeed, during Defendant’s trial, Dr. Rosendorff testified that  
22 certain extrinsic factors that identify a certain patient’s result as accurate or inaccurate would not be  
23 stored in the LIS database. *See United States v. Holmes*, 10/05/2021 Trial Transcript (“10/5 Tr.”) at  
24 2734–2737; *see also* 5/4/21 Tr. at 95 (defense counsel acknowledging LIS does not have an accuracy  
25 field). And, of course, Defendant had access to the LIS database in her role as Chief Executive Officer  
26 (until approximately June 2018) and thereafter Chair of Theranos’ Board (until the company dissolved)  
27 throughout multiple lawsuits and—if she truly thought it contained exculpatory data—she would have  
28 obtained a functioning copy of the LIS database long ago rather than waiting until the eve of her trial to

1 characterize the evidence as critical. *See* ECF No. 887 at 9 (finding no support for Defendant Holmes’  
2 assertion that she always considered the database would be exculpatory); *see also* ECF No. 846 at 11.

3 In addition, Defendant cannot demonstrate the LIS-Related Documents are material given that  
4 she has repeatedly and consistently asserted that the absence of the LIS database (and any fault therefor)  
5 relates to the patient-related counts in the TSI, of which Defendant was acquitted at trial. Her counsel  
6 has asserted as much at hearings. *See, e.g.*, 5/4/21 Tr. at 63 (“[the government] want[s] to take 1 in a  
7 million patients and put them in front of the jury [to argue] that [Defendants] were not capable of  
8 producing accurate and reliable results and now we, without the LIS database, have the burden of saying  
9 there’s no causation”), 65 (“the prejudicial impact on such anecdotal evidence just swamps any  
10 probative value based on the statistically [sic] analysis and particularly given the lack of access to the  
11 LIS to refute those allegations”), 91 (“which is where the LIS deficiency comes in, which is when you  
12 identify an anecdotal example, you need to look at the surrounding facts and circumstances to access  
13 [sic] whether there’s an issue with the technology”); 7/7 Tr. at 34–36 (“[W]ith respect to the patient  
14 counts that [information in LIS] would be exculpatory evidence . . . .”). Defendant moved to suppress  
15 other categories of evidence relevant to the patient-related counts based on the absence of the LIS  
16 database. *See* ECF No. 1577 at 16; *see also id.* (citing TSI ¶ 16, which relates to patient counts).

17 Finally, TSI ¶ 12(A) alleges at least four deficiencies with the capabilities of Theranos’  
18 proprietary analyzer about which Defendant misled investor-victims, and the accuracy and reliability  
19 problems are only one deficiency. ECF No. 469 ¶ 12(A). And, of course, Defendant’s lies to investors  
20 regarding the capabilities of Theranos’ proprietary device are themselves only one category among  
21 several misrepresentations she made. *See, e.g., id.* ¶ 12(A)–(H); ECF No. 1575 at 4–5 (referencing other  
22 misrepresentations to investor-victims in denying Defendant’s Rule 29 motion). The Court should reject  
23 Defendant’s assertion that the LIS-Related Documents are material to one subpart within a subpart of  
24 misrepresentations she made to investors when she, herself, never previously asserted as much.

#### 25 4. The LIS-Related Documents Are Cumulative and Impeachment Evidence

26 The Court should also deny Defendant’s Rule 33 Motion re: LIS-Related Documents because it  
27 relates to inadmissible, cumulative evidence that, at most, could be used as impeachment evidence if  
28 Defendant were to be granted a new trial. Defendant must also be able to show that the LIS-Related

1 Documents would be admissible. *See, e.g., United States v. Cohen*, 685 F. App'x 609, 610 (9th Cir.  
2 2017) (holding “no abuse of discretion in the district court’s finding that [defendant] failed to produce  
3 any *admissible* newly discovered evidence” (emphasis added)); *United States v. Weber*, 721 F.2d 266,  
4 268 (9th Cir. 1983) (defining “newly discovered evidence” as “admissible in court and previously  
5 unavailable to the defendant”). Defendant cannot carry her burden to show that the eleven LIS-Related  
6 Documents produced by the government in early June 2022 would even be admissible were she to be  
7 retried. At co-Defendant Balwani’s trial, with the benefit of the LIS-Related Documents, the Court  
8 admitted only one substantive email thread regarding the government’s so-called “investigatory failure”  
9 for a limited purpose of notice to the government, admitted a second email over co-Defendant’s  
10 objection showing the government’s persistence in attempting to obtain a functioning copy of the LIS,  
11 and precluded the government from asking questions about the gaps in data within the LIS database.  
12 *See* 6/9 Tr. at 6741–6743, 6784–6801. Courts are split on whether government statements are non-  
13 hearsay under Federal Rule of Evidence 801(d)(2). *See, e.g., United States v. Bakshinian*, 65 F. Supp.  
14 2d 1104, 1105–06 (C.D. Cal. 1999) (describing circuit split). Regardless of whether the statements are  
15 non-hearsay, Defendant still has to overcome other admissibility bars such as Federal Rules of Evidence  
16 401 and 403. *Id.* at 1110; *see, e.g., Hinkson*, 585 F.3d at 1265 (upholding district court’s determination  
17 that “new” evidence would be inadmissible under Rule 403 balancing test).

18 Even if the Court determines the LIS-Related Documents might be admissible, Defendant is not  
19 entitled to a new trial if such evidence is cumulative or merely impeaching. *Harrington*, 410 F.3d at  
20 601. The Court found the October 2020 Letter itself to be cumulative of the LIS-Related Documents,  
21 which strongly suggests the reverse is true as well. *See* ECF No. 1464 at 12. Her own counsel  
22 frequently referred to the topic of these emails as “not relevant to this case[,]” a “side distraction [that is]  
23 not core to this case” and would trigger a mini-trial, and thus “should be out.” 5/4/21 Tr. at 50, 55, 57–  
24 58, 94–95, 98. Furthermore, Defendant in closing arguments emphasized the “anecdotal” nature of the  
25 patient-victims the government called to testify and the lack of “statistical” evidence presented by the  
26 government. 12/17 Tr. at 9216–9227. And substantial additional evidence demonstrated Theranos’  
27 inability to provide accurate and reliable tests from its proprietary device—as but one example,  
28 Theranos itself decided to void all patient tests run on its proprietary device. *See* TX 4943.

1 Any minimal probative value in having the underlying documents in addition to the substantive  
 2 information is substantially outweighed by the confusion it would cause as well as the undue delay and  
 3 waste of time. Fed. R. Evid. 403. For example, Defendant has not suggested through which witness she  
 4 would seek to introduce these documents. While co-Defendant Balwani disclosed pretrial an expert in  
 5 Microsoft SQL databases to discuss Theranos' LIS database (ECF No. 1158), Defendant Holmes never  
 6 made a similar disclosure. She did include members of the prosecution team and government support  
 7 staff on her witness list. *See* ECF No. 1003. But the Court precluded co-Defendant Balwani from  
 8 calling members of the prosecution team and Defendant has not explained why she would fare any better  
 9 in trying to overcome the high burden she would face to do so. ECF No. 1464 at 7–8 n.3; *see, e.g.,*  
 10 *United States v. Prantil*, 764 F.2d 548, 554 (9th Cir. 1985) (“[C]ourts have generally disfavored  
 11 allowing a participating prosecutor to testify[] at a criminal trial. . . . This reluctance is understandable  
 12 particularly when the defendant seeks to call the prosecutor as a witness.”).

13 Finally, Defendant's motion exposes the true purpose for which she would seek to admit these  
 14 documents if she were granted a new trial—“to show the prosecutors' bias” (ECF No. 1577 at 11, 14,  
 15 15, 20; *cf. id.* at 19)—which is merely impeaching evidence that does not meet the difficult test under  
 16 Rule 33 for a new trial based on newly discovered evidence. *See, e.g., United States v. Waggoner*,  
 17 339 F.3d 915, 919 (9th Cir. 2003) (evidence “was cumulative, impeachment-related, or both” and thus  
 18 did not warrant a new trial).

### 19 **5. The LIS-Related Documents Would Not Result in an Acquittal**

20 Defendant's Rule 33 Motion re: LIS-Related Documents fails to meet the final factor for a new  
 21 trial based on newly discovered evidence, as well. The eleven LIS-Related Documents would not alter  
 22 the outcome in a re-trial under any standard. *See Hinkson*, 585 F.3d at 1266–67 (upholding court's  
 23 finding that “‘newly discovered’ evidence was not likely to change the result in a re-trial” where it  
 24 related to one prosecution witness and the evidence did not directly undercut the government's theory at  
 25 trial). Defendant does not describe how this “new” evidence would have altered the testimony of any of  
 26 the 32 witnesses or the balance of evidence presented against her across her four-month trial. She chose  
 27 to attach only six of the eleven emails produced to her motion (*see* ECF No. 1577-1) and does not  
 28 explain how those could possibly make a dent when compared against the more than 900 admitted

1 exhibits at her trial (*see* ECF No. 1324). Rather, she claims it would have impacted her decision  
2 whether to bring an “investigatory failure” defense as her co-Defendant did. *See* ECF No. 1577 at 10–  
3 11, 15–16, 19–20. However, as described above, Defendant Holmes had identical information as co-  
4 Defendant Balwani before their respective trials with regard to the government’s attempt to obtain a  
5 functioning copy of the LIS database. The parties and the Court discussed multiple times throughout  
6 Defendant’s trial whether she was going to present any evidence that the government was at fault for the  
7 missing LIS database, thereby opening the door under the Court’s motion *in limine* order. *See* ECF No.  
8 798 at 57–58; *see, e.g.*, 9/29 Tr. at 2371–2374; 11/10 Tr. at 5877–5889; 11/19 Tr. at 7100–7104;  
9 Exhibit 1. Doing so would have re-engaged the Court’s deferred ruling with respect to the very  
10 documents Defendant now claims would have been critical. *See* ECF No. 887 at 18. Defendant elected  
11 not to pursue the “investigatory failure” defense and her co-Defendant made the opposite decision.  
12 *Compare* Exhibit 1 *and* 11/19 Tr. at 7100–7104 (the “record is exactly where it was at the time that we  
13 first made this motion [to suppress]” since Defendant did not introduce evidence at trial regarding the  
14 government’s conduct), *with* 3/22 Tr. at 1113 (“I know that we have opened the door to something . . . .  
15 I believe the government can defend itself and argue that it wasn’t their fault.”); *cf.* ECF 1577 at 15–16.  
16 Later regret over not pursuing a trial strategy available all along does not entitle Defendant to a new  
17 trial, particularly where her co-Defendant pursued that trial strategy with unfavorable results.

18           Because of the severed trials, the Court need not speculate what the effect on the outcome would  
19 be if Defendant had the LIS-Related Documents and raised the “investigatory failure” defense as her co-  
20 Defendant did. Co-Defendant Balwani had the same information before his trial as she did, made a  
21 different strategic choice, obtained the documents with the same substantive information as the  
22 October 2020 Letter, presented an expert witness in the hopes of showing an insufficient government  
23 investigation—and was subsequently convicted on all twelve counts in the TSI. *See* ECF No. 1507.  
24 Balwani even sought the “missing evidence” jury instruction she claims she may have pursued (*see* ECF  
25 No. 1577 at 16)—to no avail. *See* 6/9 Tr. at 5879–5888. Defendant claims that the jury would acquit  
26 her on her remaining counts of conviction if she had been able to present “the prosecutors’ role in the  
27 loss of th[is] central body of evidence” (ECF No. 1577 at 19–20)—but she had that choice and rejected  
28 it (*see* Exhibit 1), and her co-Defendant pursued it and was not acquitted. Defendant simply cannot



1 meet her burden to show that these LIS-Related Documents would have had any impact whatsoever on  
2 the jury's verdict rendered against her.

3 Any attempt by Defendant to shoehorn in the importance of the LIS database to Theranos' ability  
4 to provide accurate and reliable test results should be rejected for reasons also stated above. Defendant  
5 has always claimed the missing LIS database was relevant to the patient-related counts of which she was  
6 acquitted. *See, e.g.*, 5/4/21 Tr. at 63–65, 91, 96–98; 7/7 Tr. at 34–36. The Court in the same order  
7 granting the limited production of the LIS-Related Documents precluded the parties from delving into  
8 the substance within the database. ECF No. 1464 at 3–5, 9, 12. Even in the hypothetical scenario where  
9 Defendant would be permitted to discuss the LIS database in a manner her co-Defendant was not, the  
10 accuracy and reliability of Theranos tests is one of four categories of misrepresentations made to  
11 investor-victims described in the TSI, which, in turn, is one category among seven described in the TSI  
12 that were also presented at her trial. *See* ECF No. 469 ¶ 12(A)–(H). As the government described in its  
13 briefing with respect to Defendant's Rule 29 motion, overwhelming evidence supported the jury's  
14 verdict on each of these categories, any one of which alone could uphold Defendant's conviction on the  
15 four investor-related counts. *See* ECF No. 1395, 1486. Furthermore, the jury heard directly from  
16 Defendant who testified over the course of several days, and courts have found that not credible  
17 testimony by a defendant is alone sufficient to deny a motion for a new trial. *See, e.g., United States v.*  
18 *Kenny*, 645 F.2d 1323, 1343–44 (9th Cir. 1981). It is implausible that three emails admitted during co-  
19 Defendant Balwani's trial (two of which entirely overlap in substance) would alter the jury's calculus,  
20 let alone any of the remaining eleven LIS-Related Documents with questionable admissibility. And,  
21 indeed, they did not alter the jury's calculus in co-Defendant Balwani's trial—he too was convicted on  
22 the same investor-related counts as Defendant.

23 Finally, the eleven LIS-Related Documents had nothing to do with a single element of the  
24 offense. They do not show one of Defendant's representations was true or immaterial. They do not  
25 have any bearing on her mental state. They do not have any bearing on whether interstate wires were  
26 used. As her counsel reiterated repeatedly pretrial, the substantive facts underlying the LIS-Related  
27 Documents are “not relevant to this case.” 5/4/21 Tr. at 50, 55, 57–58, 94–95, 98. There is no reason to  
28 think additional information or a mini-trial about the LIS database would yield a different result.

1 In sum, even if Defendant’s claim that old information produced in a new format was relevant to  
 2 a subpart within a subpart of the categories of false misrepresentations she made to investors, she cannot  
 3 show that it would have led to a different outcome under any standard.

4 **B. Defendant Is Not Entitled to a New Trial Because No Violation of *Brady v.***  
 5 ***Maryland*, 373 U.S. 83 (1963), Occurred**

6 Defendant’s assertion that the government committed a *Brady* violation warranting a new trial  
 7 fails for the same reasons. *See, e.g., Waggoner*, 339 F.3d at 919 & nn.4–5 (rejecting claims for a new  
 8 trial based on both “newly discovered evidence” and *Brady* violation largely because the “evidence  
 9 would not have affected the jury’s judgment on any material point” and thus the “evidence does not  
 10 undermine our confidence in the jury verdict”); *cf.* ECF No. 1577 at 9–16.

11 A defendant must establish three elements to prove a *Brady* violation warranting a new trial:  
 12 “(1) the evidence at issue must be favorable to the accused, either because it is exculpatory, or because it  
 13 is impeaching;” (2) the government suppressed the evidence; and (3) “prejudice must have ensued[,]”  
 14 meaning that, “had the evidence been disclosed to the defense, the result of the proceeding would have  
 15 been different.” *United States v. Kohring*, 637 F.3d 895, 901–02 (9th Cir. 2011) (quoting *United States*  
 16 *v. Bagley*, 473 U.S. 667, 682 (1985)). “There is a ‘reasonable probability’ of prejudice when  
 17 suppression of evidence ‘undermines confidence in the outcome of the trial.’” *Id.* at 902 (quoting *Kyles*  
 18 *v. Whitley*, 514 U.S. 419, 434 (1995)).

19 For the reasons stated above, the outcome of Defendant’s trial would not have been different if  
 20 she had the LIS-Related Documents—one need only look to how her co-Defendant fared. Moreover,  
 21 the government did not suppress the *information* and Defendant cannot demonstrate the difference  
 22 between the description in the government’s October 2020 Letter and the underlying documents are  
 23 material. Finally, the government incorporates its prior position that the LIS-Related Documents do not  
 24 constitute *Brady* material for the reasons set forth in ECF No. 1426 at 8–10.

25 **1. The LIS-Related Documents Are Not Admissible or Exculpatory**

26 The government maintains its position that the documents underlying its October 2020 Letter,  
 27 including the LIS-Related Documents, do not constitute *Brady* material. *See* ECF No. 1426 at 8–10.  
 28 The Court has repeatedly held that the government is not required to produce these materials under the

1 theory that they somehow relate to the accuracy and reliability of Theranos test results—in part because  
2 their exculpatory nature in that regard is at best speculative—and Defendant has not presented a reason  
3 to depart from those rulings. *See* ECF Nos. 887, 1326. The government maintains its position that the  
4 LIS-Related Documents contain communications favorable to the *government’s* position, rather than  
5 Defendants’, that reconstructing the LIS database would be a “herculean undertaking” or was no longer  
6 possible. *See* ECF No. 1425-3 at 7–8. And the government maintains its position that internal emails  
7 detailing several alternative paths forward to attempt to obtain a functioning copy of the LIS database  
8 after Theranos provided an inaccessible copy should be protected by work-product protections and are  
9 not sufficiently favorable to the defense to warrant production under *Brady*. *See* ECF No. 1426 at 8–10.  
10 However, the government acknowledges that the Court disagreed when it held that the LIS-Related  
11 Documents “meet the low threshold for relevance because they have a tendency—however slight—to  
12 make the facts concerning the quality or thoroughness of the Government’s investigation more or less  
13 probable.” ECF No. 1464 at 4. The Court found a slight connection between the LIS-Related  
14 Documents and a specific “newly articulated” defense that co-Defendant opted to pursue; by contrast,  
15 Defendant had the opportunity to pursue that same defense but elected not to do so. Exhibit 1.  
16 Regardless, the LIS-Related Documents are cumulative and likely inadmissible at any theoretical future  
17 re-trial for the reasons stated *supra* in Section A.4. *See, e.g., Morris v. Ylst*, 447 F.3d 735, 741 (9th Cir.  
18 2006) (failure to disclose “merely cumulative” evidence is not a *Brady* violation particularly in light of  
19 “compelling evidence of [defendant’s] guilt”).

## 20 **2. The Substance of the LIS-Related Documents Was Not Suppressed**

21 The Court should deny Defendant’s Rule 33 Motion re: LIS-Related Documents because the  
22 government disclosed the information underlying the documents in October 2020, well before the start  
23 of her trial. “*Brady* is concerned only with cases in which the government possesses information which  
24 the defendant does not.” *Carter v. Bell*, 218 F.3d 581, 601–02 (6th Cir. 2000) (finding no *Brady*  
25 violation where defense counsel knew about plea agreement with key prosecution witness but did not  
26 obtain copy of plea agreement until later). “Evidence is not ‘suppressed’ if the defendant knows or  
27 should know of the essential facts that would enable him to take advantage of it.” *United States v.*  
28 *Runyan*, 290 F.3d 223, 246 (5th Cir. 2002) (internal quotation omitted); *cf. Comstock v. Humphries*,

1 786 F.3d 701, 709 (9th Cir. 2015) (“Evidence is ‘suppressed’ where it is known to the [government] and  
2 *not disclosed* to the defendant.” (emphasis added)).

3 Here, the government did not suppress information regarding the actions it took after it received  
4 a non-functioning copy of the LIS database from Theranos’ counsel in August 2018—rather, the  
5 government disclosed the substantive information to Defendant in the October 2020 Letter. *See, e.g.,*  
6 *United States v. Skilling*, 554 F.3d 529, 583–84 (5th Cir. 2009) (information disclosed in 302s was not  
7 suppressed even if produced in a different form later), *aff’d in part and vacated in part on other*  
8 *grounds*, 561 U.S. 358 (2010); *United States v. Henderson*, 250 F. App’x 34, 38–39 (5th Cir. 2007)  
9 (unpublished) (finding the government did not suppress evidence where the substance of email at issue  
10 was provided to the defense over a month before trial and “[a]ll the relevant information from the email  
11 was disclosed in the letter”); *United States v. Wooten*, 377 F.3d 1134, 1142 (10th Cir. 2004) (“*Brady*  
12 does not require the prosecution to disclose information in a specific form or manner.”); *DeBerry v.*  
13 *Wolff*, 513 F.2d 1336, 1340 (8th Cir. 1975) (finding *Brady* “claim borders on the frivolous” where the  
14 relevant transcript was “just as available to the defendant as to the prosecutors” and thus the “evidence  
15 [was] already known by and available to [defendant] prior to trial.”); *Buchanan v. United States*, 2013  
16 WL 4761025 (S.D. Cal. Sept. 4, 2013) (“Buchanan has shown no prejudice by his having a summary [of  
17 confidential informant’s criminal history] rather than the original document.”).

### 18 **3. The LIS-Related Documents Are Not Material Because the Result of the** 19 **Proceeding Would Not Have Been Different**

20 Finally, the Court should deny Defendant’s Rule 33 Motion re: LIS-Related Documents because  
21 she cannot demonstrate prejudice. The “touchstone” of the *Brady* materiality analysis is whether  
22 Defendant “received a fair trial that resulted in a verdict ‘worthy of confidence.’” *Barker v. Fleming*,  
23 423 F.3d 1085, 1096 (9th Cir. 2005) (quoting *Kyles*, 514 U.S. at 434). This is a “retrospective” inquiry  
24 that the Court must analyze in the “context of the entire record, including the evidence each side  
25 presented at trial[.]” *United States v. Moalin*, 973 F.3d 977, 1001–02 n.17 (9th Cir. 2020) (internal  
26 quotation omitted). “The mere possibility that an item of undisclosed information might have helped the  
27 defense, or might have affected the outcome of the trial, does not establish ‘materiality’ in the  
28 constitutional sense.” *United States v. Agurs*, 427 U.S. 97, 109–10 (1976); *see also Barker*, 423 F.3d at

1 1099; *United States v. Reyes-Garcia*, No. 10-CR-348-KJM, 2011 WL 6260357, at \*3 (E.D. Cal. Dec.  
2 15, 2011) (“Speculative evidence is insufficient to warrant a new trial.”).

3 As discussed above, the “new evidence” of the eleven LIS-Related Documents is not material in  
4 that “it could not conceivably have affected the outcome of trial, even under the reduced probability  
5 standard required by *Brady*.” *Reyes-Garcia*, 2011 WL 6260357, at \*3; *see also supra* Sections A.3 &  
6 A.5. Defendant Holmes made a strategic choice at her trial—with all of the relevant information  
7 because the government disclosed it in October 2020—not to put at issue the government’s conduct or  
8 the “investigatory failure” defense. *See, e.g.*, 11/10 Tr. at 5877–5889; 11/19 Tr. at 7100–7104;  
9 Exhibit 1. Nothing in the LIS-Related Documents would materially alter the information she had before  
10 her in making that decision, particularly given how her counsel repeatedly characterized it as  
11 “irrelevant” to the case. 5/4/21 Tr. at 50, 55, 57–58, 94–95, 98. Indeed, her co-Defendant did pursue  
12 the “investigatory failure” defense with the benefit of the LIS-Related Documents, saw fit to seek to  
13 admit only one of those documents, and was still convicted of all twelve counts. *See* 6/9 Tr. at 6741–  
14 6743; ECF Nos. 1464, 1507. Defendant cannot show prejudice at not having the documents in addition  
15 to the substantive information during her trial. Nor can she show that the eleven LIS-Related  
16 Documents were relevant to a single element of her counts of conviction.

17 In sum, “[w]eighed as a whole, the evidence characterized as *Brady* material by the  
18 Defendants—all of which is marginal, ambiguous, cumulative, inadmissible, unreliable, inculpatory,  
19 irrelevant, or of negligible probative worth—falls far short of undermining [the Court’s] confidence in  
20 the verdicts.” *United States v. Sarno*, 73 F.3d 1470, 1506 (9th Cir. 1995). To the extent Defendant  
21 pursues her argument that these documents cataloguing the government’s steps to obtain a working copy  
22 of the LIS database are somehow related to the accuracy and reliability of Theranos test results  
23 themselves, “Defendant[ ]—or [her] counsel[ ]—seem unable after years of legal battles to grasp the  
24 essence of the Government’s case against them” on the investor-related counts. *Id.* “The *Brady*  
25 evidence—if such it were—tugs at loose threads hanging from the margins of the Government’s case,  
26 but in no way challenges the bulk of the evidence upon which the convictions rest.” *Id.* at 1506–07.  
27 The Court should therefore deny Defendant’s Rule 33 Motion re: LIS-Related Documents.<sup>2</sup>

28  

---

<sup>2</sup> The government also incorporates by reference its harmlessness argument and its argument that  
U.S.’ OPP’N TO DEF.’S RULE 33 MOT. RE: LIS-RELATED DOCUMENTS,  
CASE NO. 18-CR-258 EJD

1           **C.      An Evidentiary Hearing Is Unnecessary**

2           Because Defendant has not identified “new” substantive information that would be material if  
3 she were to be re-tried, the Court should exercise its discretion to deny her request for an evidentiary  
4 hearing, which is a thinly veiled attempt at a fishing expedition to question members of the prosecution  
5 team about their litigation choices. *See* ECF No. 1577 at 17–18. “The decision on whether to hold a  
6 hearing [on a new trial motion] is within the sound discretion of the trial court.” *United States v. Nace*,  
7 561 F.2d 763, 772 (9th Cir. 1977) (finding no error in denial of Rule 33 motion based on newly  
8 discovered evidence and assertion of *Brady* violation as well as denial of further evidentiary hearing);  
9 *see also United States v. Reyes-Alvarado*, 963 F.2d 1184, 1188–89 (9th Cir. 1992) (finding no abuse of  
10 discretion in district court’s holding that an evidentiary hearing was unnecessary). Given that the Court  
11 is intimately familiar with the proceedings at both severed trials—particularly as related to LIS—the  
12 Court is “well qualified to rule on the motion for a new trial based solely on the written motions and the  
13 evidence submitted” at trial. *United States v. Slatten*, 865 F.3d 767, 791–92 (D.C. Cir. 2017).

14   **CONCLUSION**

15           For the reasons stated above, the government respectfully requests that the Court deny Defendant  
16 Holmes’ Rule 33 Motion re: LIS-Related Documents (ECF No. 1577)’s request for a new trial and  
17 evidentiary hearing.

18  
19 DATED: September 21, 2022

Respectfully submitted,

STEPHANIE M. HINDS  
United States Attorney

22   /s/ Kelly I. Volkar  
23   JEFFREY B. SCHENK  
24   JOHN C. BOSTIC  
25   ROBERT S. LEACH  
26   KELLY I. VOLKAR  
   Assistant United States Attorneys

27           Defendant’s motion is untimely under *Eberhart* because it does not assert any newly discovered  
28 evidence, as described in more detail in its contemporaneously filed Opposition to Defendant Elizabeth  
Holmes’ Rule 33 Motion re: Government Argument in Balwani Trial, filed at ECF No. 1585.